0001209191-19-034738.txt : 20190605
0001209191-19-034738.hdr.sgml : 20190605
20190605162148
ACCESSION NUMBER: 0001209191-19-034738
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190603
FILED AS OF DATE: 20190605
DATE AS OF CHANGE: 20190605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scranton Richard
CENTRAL INDEX KEY: 0001709330
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 19879949
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY, SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-03
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001709330
Scranton Richard
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
Chief Scientific Officer
Common Stock
2019-06-03
4
M
0
3010
10.52
A
23111
D
Common Stock
2019-06-03
4
M
0
12500
10.81
A
35611
D
Common Stock
2019-06-03
4
S
0
15510
43.21
D
20101
D
Stock Option (Right to Buy)
10.52
2019-06-03
4
M
0
3010
0.00
D
2022-03-02
Common Stock
3010
0
D
Stock Option (Right to Buy)
10.81
2019-06-03
4
M
0
12500
0.00
D
2022-06-05
Common Stock
12500
0
D
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.14 to $43.49, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock options are fully vested.
/s/ Kristen Williams, Attorney-in-Fact
2019-06-05